We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Rockwell Medical, Inc (Rockwell Medical), is a specialty pharmaceutical company targeting anemia management in end-stage renal disease (ESRD), chronic kidney disease (CKD) and other anemia related disease areas. Triferic is the ONLY FDA APPROVED product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. In addition, Rockwell is an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates / dialysates (used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream, to dialysis providers and distributors in the U.S. and abroad. Rockwell has two Triferic formulation:
Triferic dialysate, to be launched in the first half of 2019 and Triferic IV for first half 2019 NDA submission. Rockwell Medical owns global Triferic rights and is seeking partnership ex-USA, including Europe and Japan. We have an established China partner with anticipated 2019 China NDA.